Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy

被引：0

作者：

Kim, Tae Min ^{[1
]}

Girard, Nicolas ^{[2
]}

Low, Grace Kah Mun ^{[3
]}

Zhuo, Jianmin ^{[4
]}

Yu, Dae Young ^{[5
]}

Yang, Yishen ^{[4
]}

Murota, Maiko ^{[6
]}

Lim, Cindy Thiow Koon ^{[7
]}

Kleinman, Nora J. ^{[8
]}

Cho, Byoung Chul ^{[9
]}

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Inst Curie, Inst Thorax Curie Montsouris, Paris, France

[3] Johnson & Johnson Int Singapore Pte Ltd, Med Affairs, Janssen Asia Pacif Med Affairs, Singapore, Singapore

[4] Janssen China Res & Dev, Stat & Decis Sci, Beijing, Peoples R China

[5] Janssen Asia Pacific, Real World Evidence, Seoul, South Korea

[6] Janssen Res & Dev, Global Dev, Med Affair Operat, Tokyo, Japan

[7] IQVIA Solut Asia Pte Ltd, Real World Solut, Singapore, Singapore

[8] IQVIA Hong Kong, Real World Solut, Kwai Fong, Hong Kong, Peoples R China

[9] Yonsei Univ, Dept Med Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

来源：

ACTA ONCOLOGICA | 2023年

关键词：

CHRYSALIS trial; external control; LC-SCRUM-Asia; amivantamab; EGFR exon 20 insertions; MOLECULAR HETEROGENEITY; CLINICAL-RESPONSE; ADENOCARCINOMAS;

D O I：

10.1080/0284186X.2023.2254479

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: In the single-arm CHRYSALIS trial, advanced non-small cell lung cancer patients harboring epidermal growth factor receptor (EGFR) exon 20 insertion (Exon 20ins) showed durable responses to amivantamab, an EGFR-MET bispecific antibody targeting tumors with EGFR Exon 20ins. This study compared the effectiveness of amivantamab to real-world systemic anti-cancer therapies in Japan. Patients and methods: External control patients were selected by applying CHRYSALIS eligibility to Japanese patients from LC-SCRUM-Asia. External control patients were included for every qualifying line of therapy after platinum-based chemotherapy. Propensity score weighting was applied to external control patients to adjust for differences in baseline characteristics. Outcomes were compared between external control patients, and all and Asian-only CHRYSALIS patients using weighted Cox proportional hazards regression models for progression-free survival (PFS), time to next therapy (TTNT), and overall survival (OS), and generalized estimating equations with repeated measurements for overall response rate (ORR). Results: One hundred fifteen CHRYSALIS and 94 external control patients were identified. Compared to external control patients, amivantamab-treated patients had significantly longer OS (median OS 19.88 vs 14.09months, HR [95% CI] 0.59 [0.40-0.88]), PFS (median PFS 6.74 vs 4.73months, HR 0.59 [0.45-0.78]), TTNT (median TTNT 12.16 vs 5.09months, HR 0.39 [0.29-0.53]), and significantly higher ORR (41.7% vs 14.1%). Analyses of amivantamab-treated Asian patients (n=61) showed similar clinical benefits. Conclusion: In the absence of clinical evidence from randomized clinical trials, this study reflects the benefit of amivantamab after platinum-based chemotherapy for advanced non-small cell lung cancer patients harboring EGFR Exon 20ins, compared to current real-world therapies.

引用

页码：1689 / 1697

页数：9

共 50 条

[1] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
Minchom, Anna
Viteri, Santiago
Bazhenova, Lyudmila
Gadgeel, Shirish M.
Ou, Sai-Hong Ignatius
Trigo, Jose
Bauml, Joshua M.
Backenroth, Daniel
Bhattacharya, Archan
Li, Tracy
Mahadevia, Parthiv
Girard, Nicolas
LUNG CANCER, 2022, 168 : 74 - 82
[2] Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.
Minchom, Anna Rachel
Girard, Nicolas
Bazhenova, Lyudmila
Ou, Sai-Hong Ignatius
Gadgeel, Shirish M.
Trigo, Jose
Viteri, Santiago
Backenroth, Daniel
Bhattacharya, Archan
Li, Tracy
Mahadevia, Parthiv
Bauml, Joshua
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
Spira, Alexander
Waters, Dexter
Ran, Tao
Vadagam, Pratyusha
He, Jinghua
Vanderpoel, Julie
Donnelly, Anjali
Lin, Iris
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
[4] Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Zhang, Jing
Li, Wenjie
BMC PULMONARY MEDICINE, 2025, 25 (01):
[5] Amivantamab compared with European, real-world (RW) standard of care (SoC) in adults with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), after failure of platinum-based therapy
Girard, N.
Popat, S.
Rahhali, N.
Rodrigues, B.
Schioppa, C. A.
Pick-Lauer, C.
Adamczyk, A.
Sermon, J.
Diels, J.
Penton, J.
Thomas, M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1062 - S1062
[6] Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Mok, T. S. K.
Liu, G.
Nyaw, S. F.
Curcio, H.
Cortot, A.
Kam, T. Y.
Descourt, R.
Chik, Y. K.
Cheema, P. K.
Gwinnutt, J. M.
Churchill, E. N.
Nyborn, J.
Curran, E.
Yin, Y.
Chong, K.
Tanaka-Chambers, Y.
Kretz, J.
Cadranel, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1698 - S1699
[7] Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Dersarkissian, M.
Bhak, R.
Lin, H.
Li, S.
Cheng, M.
Lax, A.
Huang, H.
Duh, M.
Ou, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S681 - S681
[8] Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
Sabari, J. K.
Shu, C. A.
Park, K.
Leighl, N.
Mitchell, P.
Kim, S.
Lee, J.
Kim, D.
Viteri, S.
Spira, A.
Han, J.
Trigo, J.
Lee, C. K.
Lee, K. H.
Girard, N.
Yang, T.
Goto, K.
Sanborn, R. E.
Yang, J. C.
Xie, J.
Roshak, A.
Thayu, M.
Knoblauch, R. E.
Cho, B. C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S108 - S109
[9] Positive CHMP Recommendation for RYBREVANT® (Amivantamab) for Treatment of adult Patients with advanced non-small cell Lung Cancer and activating EGFR Exon20 Insertion Mutations after Failure of platinum-based Therapy
不详
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (12)
[10] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
David, Gil-Sierra Manuel
del Pilar, Briceno-Casado Maria
Cristina, Moreno-Ramos
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943

← 1 2 3 4 5 →